Byetta Heart Risk Information Concealed from FDA: Memo

Administrator 50
Print Email

Recently revealed government records suggest that Amylin Pharmaceuticals may have attempted to hide information about the potential risk of heart problems from Byetta, which was a factor in the FDA’s delayed approval for a new long-lasting version of the diabetes drug that is marketed under the brand name Bydureon. Byetta (exenatide) was originally introduced in [...]
Read Full Article


You can contact us at: